Kisqali prolonged PFS for metastatic breast cancer vs. chemo

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Results from the RIGHT Choice phase II trial showed that Kisqali (ribociclib) plus endocrine therapy demonstrated a nearly one-year PFS benefit for patients with aggressive breast cancer. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
Table of Contents

YOU MAY BE INTERESTED IN

Login